Healthcare >> CEO Interviews >> August 28, 2014
Sandesh Seth is the Chairman of Actinium Pharmaceuticals, Inc. He has 20-plus years’ experience in merchant and investment banking, equity research — Laidlaw & Co. (UK) Ltd., Cowen & Co., Bear Stearns, Commonwealth Associates — and in the pharma industry — Pfizer, Warner-Lambert, SmithKline — in strategic planning, business development and R&D project management. Mr. Seth has an MBA in finance from New York University, an M.S. in the pharmaceutical sciences from the University of Oklahoma Health Center and a B.S. in chemistry from Bombay University. In addition, Mr. Seth is also Head of Healthcare Investment Banking at Laidlaw & Co. (UK) Ltd., a full-service investment banking and brokerage firm, and a director of Relmada Therapeutics Inc., a public specialty pharmaceuticals company. Profile
Mr. Seth: Essentially, what we do is combine two very common ways of treating cancer, which are radiation and
